{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T05:22:08Z","timestamp":1732944128507,"version":"3.30.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"DOI":"10.7759\/cureus.74776","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:15:36Z","timestamp":1732925736000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy for Age-Related Macular Degeneration"],"prefix":"10.7759","author":[{"given":"Saad","family":"Bidiwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review","volume":"4","author":"Khanna S","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019, 4:e000398. 10.1136\/bmjophth-2019-000398","journal-title":"BMJ Open Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112436","article-title":"New and innovative treatments for neovascular age-related macular degeneration (nAMD)","volume":"10","author":"Patel P","year":"2021","unstructured":"Patel P, Sheth V. New and innovative treatments for neovascular age-related macular degeneration (nAMD). J Clin Med. 2021, 10:2436. 10.3390\/jcm10112436","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97653","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang S","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016, 10:1857-67. 10.2147\/DDDT.S97653","journal-title":"Drug Des Devel Ther"},{"key":"ref4","article-title":"Gene Therapy for AMD","author":"Taylor R","year":"2022","unstructured":"Taylor R. Gene Therapy for AMD. EyeNet Magazine, San Francisco, CA; 2022."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/138945011794182674","article-title":"Anti-VEGF compounds in the treatment of neovascular age related macular degeneration","volume":"12","author":"Campa C","year":"2011","unstructured":"Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011, 12:173-81. 10.2174\/138945011794182674","journal-title":"Curr Drug Targets"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0484-0","article-title":"The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: systematic review and network meta-analysis","volume":"34","author":"Danyliv A","year":"2017","unstructured":"Danyliv A, Glanville J, McCool R, Ferreira A, Skelly A, Jacob RP. The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: systematic review and network meta-analysis. Adv Ther. 2017, 34:611-9. 10.1007\/s12325-017-0484-0","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1990","article-title":"Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications","volume":"37","author":"Cheung N","year":"2014","unstructured":"Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care. 2014, 37:900-5. 10.2337\/dc13-1990","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6004047","article-title":"Efficacy and safety of antivascular endothelial growth factor (anti-VEGF) in treating neovascular age-related macular degeneration (AMD): a systematic review and meta-analysis","volume":"2022","author":"Yin X","year":"2022","unstructured":"Yin X, He T, Yang S, Cui H, Jiang W. Efficacy and safety of antivascular endothelial growth factor (anti-VEGF) in treating neovascular age-related macular degeneration (AMD): a systematic review and meta-analysis. J Immunol Res. 2022, 2022:47. 10.1155\/2022\/6004047","journal-title":"J Immunol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001205","article-title":"Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment","volume":"8","author":"Hatamnejad A","year":"2023","unstructured":"Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023, 8:205. 10.1136\/bmjophth-2022-001205","journal-title":"BMJ Open Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1425707","article-title":"Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"2018","author":"Li J","year":"2018","unstructured":"Li J, Xu J, Chen Y, Zhang J, Cao Y, Lu P. Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis. J Ophthalmol. 2018, 2018:707. 10.1155\/2018\/1425707","journal-title":"J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02055-6","article-title":"Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study","volume":"21","author":"Corazza P","year":"2021","unstructured":"Corazza P, D'Alterio FM, Kabbani J, Alam MM, Mercuri S, Orlans HO, Younis S. Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmol. 2021, 21:300. 10.1186\/s12886-021-02055-6","journal-title":"BMC Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070927","article-title":"Visual outcomes of anti-VEGF treatment on neovascular age-related macular degeneration: a real-world population-based cohort study","volume":"16","author":"Korva-Gurung I","year":"2023","unstructured":"Korva-Gurung I, Kubin AM, Ohtonen P, Hautala N. Visual outcomes of anti-VEGF treatment on neovascular age-related macular degeneration: a real-world population-based cohort study. Pharmaceuticals (Basel). 2023, 16:927. 10.3390\/ph16070927","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref13","article-title":"Efficacy and cost-effectiveness of anti-VEGF treatments for age-related macular degeneration (AMD)","volume":"55","author":"Nunes RP","year":"2014","unstructured":"Nunes RP, Rodrigues E, Hirai FE, et al.. Efficacy and cost-effectiveness of anti-VEGF treatments for age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2014, 55:4939.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.4557","article-title":"Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States","volume":"138","author":"Mulligan K","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020, 138:40-7. 10.1001\/jamaophthalmol.2019.4557","journal-title":"JAMA Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252006","article-title":"Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes","volume":"16","author":"Mun Y","year":"2021","unstructured":"Mun Y, Park KH, Park SJ, Woo SJ. Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. PLoS One. 2021, 16:e0252006. 10.1371\/journal.pone.0252006","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100421","article-title":"Impact of anti-VEGF treatment and patient characteristics on vision outcomes in neovascular age-related macular degeneration: up to 6-year analysis of the AAO IRIS\u00ae Registry","volume":"4","author":"Wykoff CC","year":"2024","unstructured":"Wykoff CC, Garmo V, Tabano D, et al.. Impact of anti-VEGF treatment and patient characteristics on vision outcomes in neovascular age-related macular degeneration: up to 6-year analysis of the AAO IRIS\u00ae Registry. Ophthalmol Sci. 2024, 4:100421. 10.1016\/j.xops.2023.100421","journal-title":"Ophthalmol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20190011","article-title":"The influence of storage method on the transparency of pig crystalline lens","volume":"82","author":"Artigas C","year":"2019","unstructured":"Artigas C, Fandi\u00f1o A, Navea A, L\u00f3pez-Murcia MM, Bosch-Morell F, Araujo-Miranda R, Artigas JM. The influence of storage method on the transparency of pig crystalline lens. Arq Bras Oftalmol. 2019, 82:56-61. 10.5935\/0004-2749.20190011","journal-title":"Arq Bras Oftalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011, 364:1897-908. 10.1056\/NEJMoa1102673","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S305141","article-title":"Comparing effectiveness of three different anti-VEGF treatment regimens for neovascular age-related macular degeneration: two years' real-world clinical outcomes","volume":"15","author":"Horner F","year":"2021","unstructured":"Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R. Comparing effectiveness of three different anti-VEGF treatment regimens for neovascular age-related macular degeneration: two years' real-world clinical outcomes. Clin Ophthalmol. 2021, 15:1703-13. 10.2147\/OPTH.S305141","journal-title":"Clin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3989","article-title":"Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"138","author":"Finger RP","year":"2020","unstructured":"Finger RP, Puth MT, Schmid M, Barthelmes D, Guymer RH, Gillies M. Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. JAMA Ophthalmol. 2020, 138:1234-40. 10.1001\/jamaophthalmol.2020.3989","journal-title":"JAMA Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159125","article-title":"Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab","volume":"133","author":"Cao X","year":"2023","unstructured":"Cao X, Sanchez JC, Patel TP, et al.. Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab. J Clin Invest. 2023, 133:25. 10.1172\/JCI159125","journal-title":"J Clin Invest"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272301","article-title":"Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration","volume":"17","author":"Ozdemir S","year":"2022","unstructured":"Ozdemir S, Finkelstein E, Lee JJ, et al.. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS One. 2022, 17:e0272301. 10.1371\/journal.pone.0272301","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-017-0695-z","article-title":"\"What should I inject next?\" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD","volume":"38","author":"Pikkel J","year":"2018","unstructured":"Pikkel J, Attas S. \"What should I inject next?\" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD. Int Ophthalmol. 2018, 38:2031-9. 10.1007\/s10792-017-0695-z","journal-title":"Int Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0483-1","article-title":"A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom","volume":"34","author":"Johnston RL","year":"2017","unstructured":"Johnston RL, Carius HJ, Skelly A, Ferreira A, Milnes F, Mitchell P. A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom. Adv Ther. 2017, 34:703-12. 10.1007\/s12325-017-0483-1","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri SJ","year":"2019","unstructured":"Bakri SJ, Thorne JE, Ho AC, Ehlers JP, Schoenberger SD, Yeh S, Kim SJ. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2019, 126:55-63. 10.1016\/j.ophtha.2018.07.028","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315600-efficacy-of-anti-vascular-endothelial-growth-factor-vegf-therapy-for-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:15:37Z","timestamp":1732925737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315600-efficacy-of-anti-vascular-endothelial-growth-factor-vegf-therapy-for-age-related-macular-degeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.74776","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}